Propanc Biopharma Inc (PPCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
| 06-2020 | 06-2019 | 06-2018 | 06-2017 | 06-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 67 | 2 | 20 | 69 | 121 |
| Receivables | 2 | 5 | 6 | 8 | 29 |
| TOTAL | $69 | $91 | $61 | $82 | $363 |
| Non-Current Assets | |||||
| PPE Net | 6 | 8 | 8 | 11 | 13 |
| Other Non-Current Assets | 24 | 2 | 2 | 2 | 4 |
| TOTAL | $30 | $11 | $11 | $13 | $16 |
| Total Assets | $99 | $102 | $71 | $95 | $379 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 51 | 52 | 55 | 59 | 57 |
| Accounts payable and accrued liabilities | 842 | 917 | 1,157 | 484 | 370 |
| Accrued Expenses | 702 | 723 | 364 | 477 | 138 |
| Other current liabilities | 562 | 1,053 | 548 | 1,037 | 1,177 |
| TOTAL | $3,740 | $4,403 | $6,823 | $5,537 | $2,944 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $3,740 | $4,403 | $6,823 | $5,537 | $2,944 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 688,671 | N/A | N/A | N/A | N/A |
| Common Shares | 0 | 1 | 0 | 5 | 3 |
| Retained earnings | -55,782 | -51,041 | -45,283 | -38,244 | -30,376 |
| Other shareholders' equity | 1,226 | 1,026 | 317 | -183 | 136 |
| TOTAL | $-3,641 | $-4,301 | $-6,752 | $-5,442 | $-2,565 |
| Total Liabilities And Equity | $99 | $102 | $71 | $95 | $379 |